Skip to content

Weekday Japan business intelligence for finance professionals.

Join the list
Tokyo Brief東 京 ブ リ ー フJapan's day, wrapped and delivered by morning.
Company2 articles
Companies

SymBio Pharmaceuticals Limited

Latest Tokyo Brief coverage on SymBio Pharmaceuticals Limited, tracking filings, financial news, and market signals from Japan.

Code
4582
Exchange
TSE
Coverage
2 articles

Latest coverage

TSE:4582

  1. SymBio Secures Exclusive US Government License to Develop a Multiple Sclerosis Drug Candidate

    SymBio Pharmaceuticals has signed an exclusive global license with the US Department of Health and Human Services to develop brincidofovir against multiple sclerosis, but the programme remains in animal testing, and the company disclosed no financial terms while saying the deal will not affect its earnings forecast for the year ending December 2026.

  2. SymBio's ¥6.77bn EVO Fund Deal Could More Than Double Its Share Count

    SymBio Pharmaceuticals lined up an estimated ¥6.77bn from Cayman fund EVO Fund to keep its antiviral drug trials funded through March 2028, but the bond-and-warrant structure could swell its share count by more than 125% if every warrant is exercised.